

论文

治疗耐甲氧西林金黄色葡萄球菌感染的抗体药物

顾江, 邹全明

第三军医大学药学院 重庆 400038

摘要:

耐甲氧西林金黄色葡萄球菌(methicillin-resistant *Staphylococcus aureus*, MRSA) 作为超级细菌的典型代表,严重威胁人民群众的健康。目前经典的抗生素治疗和疫苗主动预防都无法有效控制MRSA的感染。近年来,随着抗体药物产业的兴起,诸多药物研发公司和研究人员致力于研究治疗性抗体,以期控制MRSA的感染并已经取得了很多突破。就治疗MRSA感染的抗体药物研究进展作一简要综述。

关键词: 耐甲氧西林金黄色葡萄球菌 抗体药物 临床研究

Therapeutic Antibody Drugs on the Control of Methicillin-resistant *Staphylococcus aureus*

GU Jiang, ZOU Quan-ming

College of Pharmacy, Third Military Medical University, Chongqing 400038,China

Abstract:

Methicillin-resistant *Staphylococcus aureus* (MRSA), is a typical member of superbugs and a serious threat to people's health. However current antibiotics and the active vaccination can not control immunization of MRSA infection effectively. In recent years, with the rapid development of antibody-drug industry, many drug RD companies and researchers working on therapeutic antibodies begin to focus on the development of new antibody drug to control of MRSA infection. The progress and current status of therapeutic antibodies against MRSA were discussed.

Keywords: Methicillin-resistant *Staphylococcus aureus* Therapeutic antibody Clinical trail

收稿日期 2011-11-24 修回日期 2011-12-23 网络版发布日期

分类号:

Q819

基金项目:

重庆市自然科学基金资助项目(CSTC2011jjA10071)

通讯作者: 顾江 通讯作者E_mail: jianggu2012@163.com

参考文献:

[1] Boucher H, Miller L G, Razonable R R. Serious infections caused by methicillin-resistant *Staphylococcus aureus*. Clin Infect Dis, 2010, 51(Suppl 2): S183-197.

[2] Yoong P, Pier G B. Antibody-mediated enhancement of community-acquired methicillin-resistant *Staphylococcus aureus* infection. Proc Natl Acad Sci U S A, 2010, 107(5): 2241-2246.

[3] Durai R, Ng P C, Hoque H. Methicillin-resistant *Staphylococcus aureus*: an update. AORN J, 2010, 91(5): 599-606; quiz 607-599.

扩展功能

本文信息

- Supporting info
- PDF(340KB)
- [HTML全文](KB)
- 参考文献[PDF]
- 参考文献

服务与反馈

- 把本文推荐给朋友
- 加入我的书架
- 加入引用管理器
- 引用本文
- Email Alert

本文关键词相关文章

- ▶ 耐甲氧西林金黄色葡萄球菌
- ▶ 抗体药物
- ▶ 临床研究

本文作者相关文章

PubMed

[4] Vernachio J H, Bayer A S, Ames B, et al. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both *Staphylococcus aureus* and *Staphylococcus epidermidis* infections *in vivo*. *Antimicrob Agents Chemother*, 2006, 50(2):511-518.

[5] DeJonge M, Burchfield D, Bloom B, et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. *J Pediatr*, 2007, 151(3):260-265, 265 e261.

[6] Weisman L E. Antibody for the prevention of neonatal nosocomial staphylococcal infection: a review of the literature. *Arch Pediatr*, 2007, 14(Suppl 1):31-34.

[7] Burnie J P, Matthews R C, Carter T, et al. Identification of an Immunodominant ABC Transporter in methicillin-resistant *Staphylococcus aureus* infections. *Infection and Immunity*, 2000, 68(6):3200-3209.

[8] Weichhart T, Horky M, Söllner J, et al. Functional selection of vaccine candidate peptides from *Staphylococcus aureus* whole-genome expression libraries *in vitro*. *Infection and Immunity*, 2003, 71(8):4633-4641.

[9] Reilley S, Wenzel E, Reynolds L, et al. Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers. *Antimicrob Agents Chemother*, 2005, 49(3):959-962.

[10] Weems J J, Steinberg J P, Filler S, et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of *Staphylococcus aureus* bacteremia. *Antimicrob Agents Chemother*, 2006, 50(8):2751-2755.

[11] Arrecubieta C, Matsunaga I, Asai T, et al. Vaccination with clumping factor A and fibronectin binding protein A to prevent *Staphylococcus aureus* infection of an aortic patch in mice. *J Infect Dis*, 2008, 198(4):571-575.

[12] Schaffer A C, Solinga R M, Cocchiari J, et al. Immunization with *Staphylococcus aureus* clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. *Infect Immun*, 2006, 74(4):2145-2153.

[13] Visai L, Xu Y, Casolini F, et al. Monoclonal antibodies to CNA, a collagen-binding microbial surface component recognizing adhesive matrix molecules, detach *Staphylococcus aureus* from a collagen substrate. *J Biol Chem*, 2000, 275(51):39837-39845.

[14] Benjamin D K, Schelonka R, White R, et al. A blinded, randomized, multicenter study of an intravenous *Staphylococcus aureus* immune globulin. *J Perinatol*, 2006, 26(5):290-295.

[15] Rupp M E, Holley H P, Lutz J, et al. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-*Staphylococcus aureus* capsular polysaccharide immune globulin in treatment of *Staphylococcus aureus* bacteremia. *Antimicrob Agents Chemother*, 2007, 51(12):4249-4254.

[16] Lalich I J, Sam-Agudu N A. Community-acquired methicillin-resistant *Staphylococcus aureus* necrotizing fasciitis in a healthy adolescent male. *Minn Med*, 2010, 93(9):44-46.

[17] Maira-Litran T, Kropec A, Goldmann D A, et al. Comparative opsonic and protective activities of *Staphylococcus aureus* conjugate vaccines containing native or deacetylated *Staphylococcal* Poly-N-acetyl-beta-(1-6)-glucosamine. *Infect Immun*, 2005, 73(10):6752-6762.

[18] Gauduchon V, Cozon G, Vandenesch F, et al. Neutralization of *Staphylococcus aureus* Panton Valentine leukocidin by intravenous immunoglobulin *in vitro*. *J Infect Dis*, 2004, 189(2):346-353.

[19] Ragle B E, Bubeck Wardenburg J. Anti-alpha-hemolysin monoclonal antibodies mediate protection against *Staphylococcus aureus* pneumonia. *Infect Immun*, 2009, 77(7):2712-2718.

[20] LeClaire R D, Hunt R E, Bavari S. Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. *Infect Immun*, 2002, 70(5):2278-2281.

[21] Park J, Jagasia R, Kaufmann G F, et al. Infection control by antibody disruption of bacterial quorum sensing signaling. *Chem Biol*, 2007, 14(10):1119-1127.

1. 王彩福, 张健诚, 姚宁, 苏盛. LAK细胞实验室及临床研究的进展[J]. 中国生物工程杂志, 1991,11(6): 19-22
2. 邱信芳, 薛京伦. 基因治疗研究的现状和展望[J]. 中国生物工程杂志, 1995,15(1): 18-21
3. 徐家立. 努力增加抗癌药紫杉醇的供给[J]. 中国生物工程杂志, 1992,12(5): 49-51
4. 丁锡申. 基因工程药物的审批[J]. 中国生物工程杂志, 1995,15(5): 5-7
5. 张莹, 何金生, 洪涛. 重组抗体药物研究进展及应用[J]. 中国生物工程杂志, 2009,29(08): 102-106
6. 谢建平. 专利(即将)到期生物医药产品的博弈策略[J]. 中国生物工程杂志, 2002,22(2): 91-92
7. 于源, 刘忠荣, 余孝其, 吴洽庆. 基因工程药物研制过程中相关问题探讨[J]. 中国生物工程杂志, 2005,25(10): 93-97